EGFR and non-small cell lung carcinoma: The advent of tyrosine kinase inhibitors (TKIs), including first-generation gefitinib, erlotinib, and icotinib, second-generation afatinib and dacomitinib, and third-generation osimertinib, furmonertinib, and almonertinib, has changed the treatment mode of EGFR-mutant advanced NSCLC.